BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24017961)

  • 1. Is it possible to diagnose malignancy from fluid in cystic ovarian tumors?
    Yamada R; Maeda N; Oguri H; Adachi Y; Takeuchi T; Furihata M; Fukaya T
    Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):96-100. PubMed ID: 24017961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutations in ovarian cancer: a late event?
    Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
    Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary.
    Fujita M; Enomoto T; Inoue M; Tanizawa O; Ozaki M; Rice JM; Nomura T
    Jpn J Cancer Res; 1994 Dec; 85(12):1247-56. PubMed ID: 7852189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
    Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
    Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of p53 mutation in the carcinomas arising from endometriosis.
    Akahane T; Sekizawa A; Purwosunu Y; Nagatsuka M; Okai T
    Int J Gynecol Pathol; 2007 Jul; 26(3):345-51. PubMed ID: 17581423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 tumor suppressor gene mutation in ovarian cancer in Thai patients.
    Neungton N; Neungton S; Leelaphatanadit C; Dangrat C; Soiampornkul R
    J Med Assoc Thai; 2002 Jun; 85(6):658-67. PubMed ID: 12322838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Detection and sequence analysis of the p53 gene mutation in epithelial ovarian cancer].
    Guan X; Lang J; Bian M
    Zhonghua Fu Chan Ke Za Zhi; 1998 Mar; 33(3):165-7. PubMed ID: 10682487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of the p53 gene in human functional adrenal neoplasms.
    Lin SR; Lee YJ; Tsai JH
    J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection.
    Fujita M; Inoue M; Tanizawa O; Iwamoto S; Enomoto T
    Cancer Res; 1992 Oct; 52(19):5323-8. PubMed ID: 1327506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
    Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
    Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.
    Wang YC; Chen CY; Chen SK; Cherng SH; Ho WL; Lee H
    Cancer Res; 1998 Jan; 58(2):328-33. PubMed ID: 9443413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of p53 gene in gastric carcinoma in Taiwan.
    Wang JY; Lin SR; Hsieh JS; Hsu CH; Huang YS; Huang TJ
    Anticancer Res; 2001; 21(1B):513-20. PubMed ID: 11299797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian transitional cell carcinoma represents a poorly differentiated form of high-grade serous or endometrioid adenocarcinoma.
    Takeuchi T; Ohishi Y; Imamura H; Aman M; Shida K; Kobayashi H; Kato K; Oda Y
    Am J Surg Pathol; 2013 Jul; 37(7):1091-9. PubMed ID: 23681072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 expression, mutation, and allelic deletion in ovarian cancer.
    McManus DT; Yap EP; Maxwell P; Russell SE; Toner PG; McGee JO
    J Pathol; 1994 Nov; 174(3):159-68. PubMed ID: 7823248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation in epithelial ovarian carcinoma and borderline ovarian tumor.
    Lee JH; Kang YS; Park SY; Kim BG; Lee ED; Lee KH; Park KB; Kavanagh JJ; Wharton JT
    Cancer Genet Cytogenet; 1995 Nov; 85(1):43-50. PubMed ID: 8536236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.